Fig. 3From: Higher pharmaceutical public expenditure after direct price control: improved access or induced demand? The Colombian case(Source: Data are from July 2011 to December 2015, SISMED 2011–2015)Price index and real health expenditure for regulated versus non-regulated drugsBack to article page